The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Wouter Latour Biography and Net Worth

Director of Vaxart

Dr. Latour has served as our Chairman of the Board since December 2019, as a member of our board of directors since October 2011 and Chief Executive Officer from September 2011 to June 2020. From June to September 2011, Dr. Latour served as our Chief Operating Officer. Prior to that role, Dr. Latour was Chief Executive Officer and a member of the board of directors of Trinity Biosystems, Inc., a biopharmaceutical company. Dr. Latour previously held executive positions at various pharmaceutical and biotechnology companies including Genelabs, SmithKline Biologicals and Novartis. Dr. Latour received an M.D. from the University of Amsterdam and an M.B.A. from Stanford University.

What is Wouter Latour's net worth?: The estimated net worth of Wouter Latour is at least $71,430.00 as of May 7th, 2021. Dr. Latour owns 100,000 shares of Vaxart stock worth more than $71,430 as of November 14th. This net worth estimate does not reflect any other assets that Dr. Latour may own. Learn More about Wouter Latour's net worth.
How do I contact Wouter Latour?: The corporate mailing address for Dr. Latour and other Vaxart executives is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. Vaxart can also be reached via phone at (650) 550-3500 and via email at [email protected]. Learn More on Wouter Latour's contact information.
Has Wouter Latour been buying or selling shares of Vaxart?: Wouter Latour has not been actively trading shares of Vaxart in the last ninety days. Most recently, Wouter Latour sold 100,000 shares of the business's stock in a transaction on Friday, May 7th. The shares were sold at an average price of $7.13, for a transaction totalling $713,000.00. Following the completion of the sale, the director now directly owns 100,000 shares of the company's stock, valued at $713,000. Learn More on Wouter Latour's trading history.
Who are Vaxart's active insiders?: Vaxart's insider roster includes Margaret Echerd (SVP), Wouter Latour (Director), and Sean Tucker (SVP). Learn More on Vaxart's active insiders.
Are insiders buying or selling shares of Vaxart?: During the last year, Vaxart insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $13,600.00. The most recent insider tranaction occured on June, 18th when Director W. Mark Watson bought 20,000 shares worth more than $13,600.00. Insiders at Vaxart own 2.6% of the company. Learn More about insider trades at Vaxart.
Information on this page was last updated on 6/18/2024.

Wouter Latour Insider Trading History at Vaxart

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/7/2021	Sell	100,000	$7.13	$713,000.00	100,000
11/23/2020	Sell	333,334	$6.32	$2,106,670.88
9/30/2019	Buy	166,667	$0.30	$50,000.10

Wouter Latour Buying and Selling Activity at Vaxart

Vaxart Company Overview

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Today's Range

Now: $0.63

$0.63

$0.69

50 Day Range

MA: $0.82

$0.69

$0.99

2 Week Range

Now: $0.63

$0.52

$1.54

Volume

2,492,972 shs

Average Volume

2,487,540 shs

Market Capitalization

$111.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Financial Prophecy

From Porter & Company | Ad